HIV&HEP 2023
Meeting category
Date(s)
7 Jun 2023 - 9 Jun 2023
Location
Rome, Italy
Meeting type
Hybrid Meeting
CME Credits
6
Organizer

European Meeting on HIV & Hepatitis 2023

Related Enduring Materials

Enduring Materials

Day 1 - Wednesday, 7 June 2023

- 16:00
16:00 CEST
Welcome Coffee
Opening of the HIV & Hepatitis Meeting -
17:05 CEST
Andrea De Luca Lecture - Toxicity of Antiretroviral Drugs: What’s Important in 2023?
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
17:25 CEST
Charles Boucher Lecture: The Düsseldorf Patient
17:45 CEST
1# Abstract:• Extensive Virologic Characterization in a Person Living with HIV with Apparent HIV Remission for 2 years After Allogeneic Stem Cell Transplantation with CCR5 Wild-Type Cells: A Case Study
Lia Fiaschi
University of Siena, Italy
17:55 CEST
Discussion & Close of the Day
18:00 CEST
Networking Reception & Poster Viewing

Day 2 - Thursday, 8 June 2023

Session 1: Update on (Re)emerging Viral Infections / COVID / RSV -
08:30 CEST
Diagnosis Respiratory Viruses: Point-of-Care Testing & PCR
Carlo Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Italy
08:50 CEST
State-of-the-Art: COVID - Clinical Management
Cristina Mussini, MD
Università degli Studi di Modena e Reggio Emilia, Italy
09:10 CEST
State-of-the-Art: RSV - Prevention & Treatment
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France
09:30 CEST
2# Abstract: SARS-COV-2 Omicron Variability: Focus in Immunocompromised Individuals
Maria Concetta Bellocchi
Tor Vergata University of Rome, Italy
09:40 CEST
3# Abstract: Epidemiology and Molecular Analyses of Respiratory Syncytial Virus in the Season 2021‐2022 in Northern Italy
Alessia Lai
University of Milan, Italy
09:50 CEST
Discussion
10:05 CEST
Coffee Break & Poster Viewing
Session 2: HIV Prevention -
10:30 CEST
HIV Prevention: Barriers and Facilitators of PrEP Access
10:50 CEST
HIV Prevention - Community Perspective
11:10 CEST
4# Abstract: Expanding PrEP by 50% of the Current Users on Long-Acting Cabotegravir vs Daily-Oral TDF/FTC PrEP will have a Similar Impact in Reaching the UNAIDS Goal to Reduce New Infections by 2030 Among MSM in the Netherlands. A Modeling Study
Shreoshee Mukherjee
Erasmus University Medical Center, the Netherlands
11:20 CEST
Discussion
Session 3: Diagnostics and Surveillance for HIV -
11:35 CEST
State-of-the-Art Lecture: Diagnostics for HIV Drug Resistance Surveillance
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
11:55 CEST
HIV Subtypes: Update on Global Distribution and Impact on Diagnosis and Treatment
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
12:15 CEST
5# Abstract: Binational Dimensions of Human Immunodeficiency Virus-1 A6 Variant Clustering Pattern in Ukrainian Migrants Diagnosed in Poland
Karol Serwin
Pomeranian Medical University, Poland
12:25 CEST
6# Abstract: Use of Genotypic HIV DNA Resistance Testing: French DELPHI-type Consensus
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
12:35 CEST
7# Abstract: Factors Associated with M184V Mutation Clearance in the HIV Reservoir Over Time
Vincent Calvez
Institut Pierre Louis d’Epidémiologie et de Santé Publique, France
12:45 CEST
Discussion
13:00 CEST
Lunch
Session 4: Bridging Virology, Clinical Innovations Across Europe - Next Generation Sequencing -
13:50 CEST
Update on NGS Platforms for HIV and SARS-CoV-2 Resistance and Whole Genome Analysis
14:10 CEST
Different Algorithms and Websites for Virus Evolution and Resistance Interpretation
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France
14:30 CEST
Clinical Relevance and Real Practice Use of HIV-1 NGS Results
Maria Santoro, PhD
University of Rome "Tor Vergata", Italy
14:50 CEST
8# Abstract: Comparison of Different HIV-1 Resistance Interpretation Tools for Next Generation Sequencing in Italy
Daniele Armenia, PhD
Saint Camillus International University of Health Sciences, Italy
15:00 CEST
Discussion
15:15 CEST
Coffee Break
Session 5: Clinical Management -
15:35 CEST
The Clinical Relevance of Integrase Resistance
Charlotte Charpentier, PharmD, PhD
Hôpital Bichat-Claude Bernard, France
15:55 CEST
9# Abstract: Evaluation of HIV-1 DNA Resistance Burden through NGS in Highly Treatment-Experienced Multi-Resistant Individuals under Virological Control Enrolled in the PRESTIGIO Registry
Daniele Armenia, PhD
Saint Camillus International University of Health Sciences, Italy
16:05 CEST
Case Discussion 1
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
16:25 CEST
Case Discussion 2
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
16:45 CEST
Discussion
17:00 CEST
End of the Plenary Program
Guided Poster Tours & Networking Dinner - 17:00
17:00 CEST
Guided Poster Tours
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
Federico García, PharmD, PhD
Hospital Universitario San Cecilio, Spain
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
19:00 CEST
Networking Dinner

Day 3 - Friday, 9 June 2023

Session 6: Long-Acting Antiretrovirals - Knowns/ Unknowns -
08:30 CEST
Practical/Clinical Considerations When Prescribing LA-ARVs
Monica Gandhi, MD, MPH
University of California San Francisco, United States
08:50 CEST
10# Abstract: Insufficient Drug Levels with Cabotegravir/Rilpivirin Based Long Acting Therapy
Robert Ehret
MVZ mib AG, Germany
09:00 CEST
11# Abstract: Prevalence of Underlying Viral Factors Associated with Treatment Failure in the Long-Acting Cabotegravir-Rilpivirine Regimen
Federico García, PharmD, PhD
Hospital Universitario San Cecilio, Spain
09:10 CEST
Q & A
09:25 CEST
Roundtable Discussion: Identifying and Overcoming Challenges to Durable Adherence to Long-Acting Agents
Monica Gandhi, MD, MPH
University of California San Francisco, United States
Gary Rubin, MD, MCFP, AAHIVS
University of Toronto, Canada
Darrell H. S. Tan, MD, FRCPC, PhD
St. Michael's Hospital, Canada
09:45 CEST
Coffee Break
Session 7: What is in the Pipeline? Presentations on Future Therapeutics and Vaccines from Industry - non-CME
non-CME
The full program of "Session 7: What is in the Pipeline?" can be visited in the "Industry Program" Tab
Industry Symposium - non-CME
non-CME
The full program of the "Industry Symposium" session can be visited in the "Industry Program" Tab
13:00 CEST
Lunch
Session 8: Update in Clinical Management of Viral Hepatitis -
14:00 CEST
Emerging Data on Hepatitis E
Christophe Rodriguez, PharmD, PhD
Henri Mondor University Hospital, France / Paris-Est University, France
14:20 CEST
Update on Hepatitis Delta
Maria Buti, MD, PhD
Hospital General Universitari Valle Hebron, Spain
14:40 CEST
Current & Future HBV Management and Cure
Pietro Lampertico, MD, PhD
University of Milan, Italy
15:00 CEST
Charles Boucher Award Winner Abstract: Hepatitis B Virus-Specific CD4 T Cell Responses Differentiate Functional Cure from Chronic Surface Antigen+ Infection
Suzan Dijkstra
Massachusetts General Hospital and Harvard Medical School, United States
15:10 CEST
12# Abstract: Kinetics of the Three HBsAg Isoforms along with HDV-RNA Predict Virological Response in CHD Patients Treated with Bulevirtide for 48 Weeks
Stefano D'Anna
Tor Vergata University of Rome, Italy
15:20 CEST
13# Abstract: Intrahepatic HDV Replication is Sustained by an Abundant Production of HBsAg Derived from Integrated HBV-DNA, and is Not Strictly Dependent from the Extent of HBV Reservoir
Romina Salpini
Tor Vergata University of Rome, Italy
15:30 CEST
Discussion
- 15:35
15:35 CEST
Ricardo Camacho Award & Closing Remarks
15:45 CEST
End of the meeting
Overview
Welcome

The European Meeting on HIV & Hepatitis 2023 took place from 7 - 9 June 2023 in Rome, Italy.

Founded more than twenty years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. This workshop places emphasis in particular on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, as well as emerging viruses throughout Europe.

In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.

What's New

  • The confirmed venue for the Networking Dinner was at the following restaurant:

          Address: 
         Nanà Vini e Cucina
         Via della Panetteria, 37
         00187 Roma RM
         ​​​​​Italy

         Distance from the meeting venue: 350 m (4-min walking)

  • We were glad to inform that the European Meeting on HIV & Hepatitis 2023 has received COMPLIANT status from Ethical MedTech Europe platform.

  • The confirmed venue details for the European Meeting on HIV & Hepatitis 2023 can be found below.
     

    Address: 
    Roma Eventi Fontana Di Trevi
    Piazza della Pilotta, 4
    00187 Roma
    Italy

    Distance from Leonardo da Vinci International Airport (FCO): 31 km

General Information 
Who Should Attend?
Primary: Europe-based clinicians/physicians and researchers involved in the fields of HIV, HBV, and HCV.

Secondary: Laboratory managers, technicians, pharmacists, and pharmacologists.
Meeting Objectives
This meeting aims to:

- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting;

- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;

- Map important current studies and results;

- Translate new data into treatment guidelines; and

- Educate clinicians on how to best implement current and new drugs in clinical practice.
Learning Objectives
After participating in this activity, participants will be able to:

- Summarize recent results (including clinical trial results) in drug development for HIV or Hepatitis.

- Apply the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.

- Identify future challenges in the screening, monitoring and diagnosis of patients living with HIV or Hepatitis and develop new concepts for research and care strategies.
Practical Information 
Ethical MedTech
We are glad to inform that the European Meeting on HIV & Hepatitis 2023 has received COMPLIANT status from Ethical MedTech Europe platform.

For more information, you can visit the website of Ethical MedTech EU with the following link: https://www.ethicalmedtech.eu/
Venue
Address:
Roma Eventi Fontana Di Trevi
Piazza della Pilotta, 4
00187 Roma
Italy

Distance from Leonardo da Vinci International Airport (FCO): 31 km
Networking Dinner
Networking Dinner Venue:
Nanà Vini e Cucina
Via della Panetteria, 37
00187 Roma RM
Italy
Distance from the meeting venue: 350 m (4-min walking)
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the meeting is English. Translation will not be provided.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Industry Program

Day 3 - Friday, 9 June 2023

Session 7: What is in the Pipeline? Presentations on Future Therapeutics and Vaccines from Industry -
Session Chair:
10:15 CEST
ViiV
Harmony Garges, MD, MPH
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United States
10:35 CEST
Gilead
Calvin Cohen, MD, MSc
Executive Director, Global HIV Medical Affairs, Gilead Sciences, United States
10:55 CEST
Merck/MSD
11:15 CEST
Moderna
11:35 CEST
Discussion
Satellite Symposium ViiV Healthcare: Archived or Not Archived Mutations? That is the Question in the Modern Management of HIV - 12:00
12:00 CEST
Welcome and Introduction
Maria Santoro, PhD
University of Rome "Tor Vergata", Italy
12:10 CEST
Virology Perspectives of Archived Mutations
Thibault Mesplède, MSc, PhD
Erasmus Medical Centre, The Netherlands
12:25 CEST
What Matters for Clinical Decisions?
Carlo Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Italy
12:40 CEST
Panel Discussion and Q&A
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
Maria Santoro, PhD
University of Rome "Tor Vergata", Italy
12:55 CEST
Conclusion and Close
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
13:00 CEST
Lunch
Registration

The registration for the European Meeting on HIV & Hepatitis 2023 is now closed.

Fees and Conditions

Regular Delegate
In-Person

Regular Delegate
Virtual

Industry*
 

Early Fee (payment before/on 1 October 2022)

€495.00

€247.50

€1,645.00

Standard Fee (payment before/on 4 June 2023)

€895.00

€447,50

€2,045.00

Onsite/Same Day Fee (Payment on/after 5 June 2023)

€1,095.00

€547.50

€2,245.00

Discounts

Early-Career Investigators / Regular Delegates from Resource-Limited Settings (RLS)** WITH accepted abstract

Free Registration

Early-Career Investigators / Regular Delegates from Resource-Limited Settings (RLS)** WITHOUT accepted abstract

50% Off Current Regular Delegate Fee

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Regular Delegate Fee

Members of Endorsers

25% Off Current Regular Delegate Fee

Sponsors

Contact Secretariat

*Industry representatives may receive a discount based on the level of support provided to the event. For more support and registration information, please contact Jesper.Niesen@amededu.com.

**Countries included in the low-income and middle-income economies list of the World Bank Classification

If you have financial concerns or are eligible for a discount, please contact Michelle.Wu@amededu.com.

Important
  • Please find below the AIFA Authorization procedure.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

Registration Fee Includes
For onsite attendees:
- Access to all scientific sessions, including poster area;
- Conference pack, including abstract book and program;
- Refreshments during the coffee breaks;
- Buffet lunch on meeting days;
- Complimentary entrance to the Networking Reception*

* The Networking Reception will take place in the same venue of the meeting, at Roma Eventi Fontana Di Trevi, and will not have any music / entertainment of any shape or form. The Networking Reception only offers finger foods and the opportunity to have a look at the chosen abstract poster presentations.

For virtual attendees only:
- Access to all scientific sessions
- Digital workshop pack, including the digital program book

IMPORTANT:
- No day rate is available

- The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €60 is charged. Pre-booking is required via the conference secretariat. The location of the dinner will be announced shortly.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact Michelle.Wu@amededu.com.
Early-Career Investigators / Academia from Resource-limited Settings (RLS)
We are pleased to offer free registration to early-career investigators and academia from low-income and lower-middle-income countries with an accepted abstract and a 50% discount on the registration fee without an accepted abstract.

IMPORTANT: Free registration is offered to the presenting author only.

To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
AIFA Authorization Procedure
Any local or international pharmaceutical companies who wish to participate in this workshop should submit a request for authorization to AIFA (Italian Medicines Agency) per article 124 of Italian legislative decree 219 / 2006.

Local and international pharmaceutical companies are required to obtain authorization from AIFA. Requests to AIFA must be submitted 60 days before the workshop. Complete information regarding this process is available on the AIFA website: https://www.aifa.gov.it/en/acc

Should you require assistance submitting your application to AIFA, please get in touch with Fargo International with the company’s SIS code. They will assist you with the application process.

International companies with affiliates in Italy are recommended to contact their local offices, as they are informed about this procedure and can provide assistance if required.
Payment
By credit card only: online or by written authorization (see online registration). If this is not possible, please contact Michelle.Wu@amededu.com.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 8 May 2023: 50% refund (minus an administration fee of €40)

- Cancellation after 8 May 2023: Unfortunately, no refund will be given

If you are unable to attend the conference, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 22 May 2023. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the Conference, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@virology-education.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2022 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Abstracts
Abstract Submission is now closed.
Abstracts
  • The European Meeting on HIV & Hepatitis 2023 accepted new original data as well as encored abstracts. All abstracts must focus on the European region and contain up-to-date information at the time of the meeting. 
  • Complimentary registration is given to early-career professionals with an accepted abstract. A 50% discount is offered to early-career professionals without an accepted abstract. The requirements for the application are specified under the "Registration" tab.

  • Abstract submitters are encouraged to use person-first language in their abstracts. View our guidelines here

Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

Abstract Categories:
- Clinical Case
- Clinical Research on HIV and Co-Infections
- Clinical Implications of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Management of COVID-19
- HIV Inflammation and Cure
- HIV Prevention, Strategies and Implementation
- Mechanism of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Novel Diagnostic Technologies & Approaches
- Resistance to Antiviral Drugs (Hepatitis B, Hepatitis C and HIV)
- Spread of Drug Resistance
- Therapeutic Challenges in Resource-Limited Settings
- Treatment Strategies for People Living with HIV / Hepatitis
- Viral Evolution & Genetic Diversity
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.

We encourage you to use person-first language in your abstract(s). View our guidelines here: https://academicmedicaleducation.com/person-first-language
Abstract Submission
Authors can submit their abstracts electronically until the deadline. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Poster Presentation Instructions
Posters need to meet the following dimensions: A0 size (approx 33" x 47"), portrait format

Once on site:
Poster presenters are requested to stand near their posters during the poster session.
We advise you to prepare hand-outs of your poster in Letter or A4 format.
Please hang your posters as early as possible. All posters must be displayed from the opening session to the closure of the meeting.
Pushpins, velcro, or double-sided tape will be provided.
Committees
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, they participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Ana B. Abecasis, MD, PhD, PharmD - Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Universidade NOVA de Lisboa, Portugal

  • Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia

  • Stéphane Chevaliez, PharmD, PhD - University of Paris-Est Creteil, France

  • Federico García, PharmD, PhD - Hospital Universitario San Cecilio, Spain

  • Rolf Kaiser, PhD - University of Cologne, Germany

  • Leon Kostrikis, PhD - University of Cyprus, Cyprus

  • Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, United Kingdom

  • Anne-Geneviève Marcelin, MD - Hôpital Pitié-Salpétrière Paris, France

  • Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands

  • Roger Paredes, MD, PhD IrsiCaixa AIDS Research Institute, Spain

  • Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia

  • Gary Rubin, MD - University of Toronto, Canada

  • AnneMieke Vandamme, PhD - University of Leuven, Belgium

  • Maria Santoro, MD - University of Rome "Tor Vergata", Italy
  • Anders Sönnerborg, MD, PhD - Karolinska Institute, Sweden

  • Janusz Stanczak, PhD - University of Warsaw, Poland

  • Linos Vandekerckhove, MD, PhD - Ghent University Hospital, Belgium

  • Jens Verheyen, MD, PhD - Institute of Immunology and Genetics, Germany

  • David van de Vijver, PharmD, PhD - Erasmus University Rotterdam, the Netherlands

  • Hauke Walter, MDMedizinisches Labor Stendhal, Germany

  • Annemarie Wensing, MD, PhD - University Medical Center Utrecht, the Netherlands

  • Maurizio Zazzi, PhD - University of Siena, Italy

Endorsers
Accreditation
EACCME® Accreditation
UEMS

European Meeting on HIV & Hepatitis 2023, Rome, Italy 07/06/2023-09/06/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 6 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Support
Platinum Level
Silver Level
Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting.
Support Our Initiative

Financial backing to the European Meeting on HIV & Hepatitis 2023 helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in HIV & Hepatitis in the European region.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored support package by contacting Jesper Niesen at Jesper.Niesen@amededu.com or call +31 30 230 7140.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgement during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgement on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Venue
Venue

The confirmed venue details for the European Meeting on HIV & Hepatitis 2023 can be found below.

  • Meeting Venue: Roma Eventi Fontana Di Trevi 
  • Website: www.roma-eventi.com/ita/fontana-di-trevi
  • Address: Piazza della Pilotta, 4, 00187 Roma, Italy (please click here to view the map).
  • Distance from Leonardo da Vinci International Airport (FCO): 31 km

In case you have any questions or concerns regarding the venue, please feel free to contact us at Michelle.Wu@amededu.com

Previous Editions
Media
Group Photo
EuropeanHIVHep2023_GroupPhoto